Drugs.com - Clinical Trials

Cellenkos Announces US FDA Orphan Drug Designation Granted to CK0801 (Allogeneic Cord Blood derived T regulatory Cell Product) for Treatment of Aplastic Anemia

Cellenkos Announces US FDA Orphan Drug Designation Gran...

Apr 17, 2025 0

HOUSTON, April 14, 2025 /PRNewswire/ -- Cellenkos Inc., a clinical-stage biotech...

Allogene Granted Three U.S. FDA Fast Track Designations (FTD) for ALLO-329, a Next-Generation Dual-Targeted CD19/CD70 Allogeneic CAR T, for the Treatment of Lupus, Myositis and Scleroderma

Allogene Granted Three U.S. FDA Fast Track Designations...

Apr 16, 2025 0

SOUTH SAN FRANCISCO, Calif., April 07, 2025 (GLOBE NEWSWIRE) -- Allogene Therape...

Precision BioSciences Receives U.S. FDA Fast Track Designation for PBGENE-HBV, a First-In-Class Gene Editing Therapy Designed to Eliminate the Root Cause of Chronic Hepatitis B

Precision BioSciences Receives U.S. FDA Fast Track Desi...

Apr 16, 2025 0

DURHAM, N.C.--(BUSINESS WIRE)--Apr. 15, 2025-- Precision BioSciences, Inc. (Nasd...

Repurposing Blood Pressure Drug Reserpine May Prevent Vision Loss in Inherited Blinding Diseases

Repurposing Blood Pressure Drug Reserpine May Prevent V...

Apr 15, 2025 0

Tuesday, April 15, 2025 -- New studies in rats suggest the drug reserpine, appro...

Novo Nordisk Warns Consumers About Counterfeit Ozempic (semaglutide) Injection 1 mg in the US

Novo Nordisk Warns Consumers About Counterfeit Ozempic ...

Apr 15, 2025 0

PLAINSBORO, N.J., April 14, 2025 /PRNewswire/ -- Novo Nordisk has become aware o...

Ironwood Pharmaceuticals Provides Clinical and Regulatory Update on Apraglutide

Ironwood Pharmaceuticals Provides Clinical and Regulato...

Apr 14, 2025 0

BOSTON--(BUSINESS WIRE) April 14, 2025 -- Ironwood Pharmaceuticals, Inc. (Nasda...

Pfizer Discontinues Development of Oral GLP-1 Receptor Agonist Danuglipron

Pfizer Discontinues Development of Oral GLP-1 Receptor ...

Apr 14, 2025 0

NEW YORK--(BUSINESS WIRE) April 14, 2025 -- Pfizer Inc. (NYSE: PFE) today announ...

Verve Therapeutics Receives U.S. FDA Fast Track Designation for VERVE-102, an In Vivo Base Editing Medicine Targeting PCSK9

Verve Therapeutics Receives U.S. FDA Fast Track Designa...

Apr 14, 2025 0

BOSTON, April 11, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage ...

Icotrokinra Results Show 75% of Adolescents with Plaque...

Apr 10, 2025 0

SPRING HOUSE, Pa. (April 10, 2025) – Johnson & Johnson (NYSE: JNJ) today announc...

Tolebrutinib Phase 3 Data Published in NEJM Demonstrate Benefit on Disability Progression in Multiple Sclerosis

Tolebrutinib Phase 3 Data Published in NEJM Demonstrate...

Apr 10, 2025 0

Paris, April 8, 2025. The New England Journal of Medicine (NEJM) published posit...

BeiGene Provides Update on the Ociperlimab (BGB-A1217) Clinical Development Program

BeiGene Provides Update on the Ociperlimab (BGB-A1217) ...

Apr 8, 2025 0

SAN CARLOS, Calif.--(BUSINESS WIRE) April 3, 2025 -- BeiGene, Ltd. (NASDAQ: ONC;...

Mineralys Therapeutics Announces Late-Breaking Data from Advance-HTN Pivotal Trial of Lorundrostat in Uncontrolled and Resistant Hypertension

Mineralys Therapeutics Announces Late-Breaking Data fro...

Apr 8, 2025 0

RADNOR, Pa., March 29, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Na...

Biogen’s Investigational Tau-Targeting Therapy BIIB080 Receives FDA Fast Track Designation for the Treatment of Alzheimer’s Disease

Biogen’s Investigational Tau-Targeting Therapy BIIB080 ...

Apr 8, 2025 0

CAMBRIDGE, Mass., April 02, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) ...

Genentech and Roche Present Novel Therapeutic and Diagnostic Advancements in Alzheimer’s at AD/PD 2025

Genentech and Roche Present Novel Therapeutic and Diagn...

Apr 8, 2025 0

South San Francisco, CA -- April 3, 2025 -- Genentech, a member of the Roche Gro...

Rilzabrutinib Granted Orphan Drug Designation in the US for Two Rare Diseases with No Approved Medicines

Rilzabrutinib Granted Orphan Drug Designation in the US...

Apr 8, 2025 0

Paris, April 3, 2025. The US Food and Drug Administration (FDA) has granted orph...

Vividion Therapeutics Doses First Patient in Phase I Study of RAS-PI3Kα Inhibitor VVD-159642 for Treatment of Advanced Solid Tumors

Vividion Therapeutics Doses First Patient in Phase I St...

Apr 8, 2025 0

San Diego, CA, USA, Berlin, Germany, April 3, 2025 – Vividion Therapeutics, Inc....

Theravance Biopharma Presents Two New Ampreloxetine Analyses

Theravance Biopharma Presents Two New Ampreloxetine Ana...

Apr 8, 2025 0

DUBLIN, April 7, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Bi...

Primary Endpoint Met in Corcept’s Pivotal Phase 3 ROSELLA Trial of Relacorilant in Patients with Platinum-Resistant Ovarian Cancer

Primary Endpoint Met in Corcept’s Pivotal Phase 3 ROSEL...

Apr 1, 2025 0

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Mar. 31, 2025-- Corcept Therapeutics Inco...

AZD0780, a Novel Oral PCSK9 Inhibitor, Demonstrated Significant LDL Cholesterol (LDL-C) Reduction in PURSUIT Phase IIb Trial

AZD0780, a Novel Oral PCSK9 Inhibitor, Demonstrated Sig...

Apr 1, 2025 0

31 March 2025 -- Positive results from the PURSUIT Phase IIb trial for AstraZene...

Lilly's Lepodisiran Reduced Levels of Genetically Inherited Heart Disease Risk Factor, Lipoprotein(a), by Nearly 94% from Baseline at the Highest Tested Dose in Adults with Elevated Levels

Lilly's Lepodisiran Reduced Levels of Genetically Inher...

Apr 1, 2025 0

INDIANAPOLIS, March 30, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) t...

Merck’s Investigational Subcutaneous Pembrolizumab With Berahyaluronidase Alfa Demonstrates Noninferior Pharmacokinetics Compared to Intravenous (IV) Keytruda® (pembrolizumab) in Pivotal 3475A-D77 Trial

Merck’s Investigational Subcutaneous Pembrolizumab With...

Mar 29, 2025 0

RAHWAY, N.J.--(BUSINESS WIRE) March 27, 2025 -- Merck (NYSE: MRK), known as MSD...

Chlamydia Vaccine Candidate Granted Fast Track Designation by the US FDA

Chlamydia Vaccine Candidate Granted Fast Track Designat...

Mar 26, 2025 0

Paris, March 26, 2025. The US Food and Drug Administration has granted fast trac...

Omeros Corporation Provides Update of Ongoing Zaltenibart Phase 3 PNH Clinical Trial Program

Omeros Corporation Provides Update of Ongoing Zalteniba...

Mar 26, 2025 0

SEATTLE--(BUSINESS WIRE)--Mar. 21, 2025-- Omeros Corporation (Nasdaq: OMER) toda...

Palatin’s Oral MC4R Agonist PL7737 Receives FDA Orphan Drug Designation for Obesity Due to Leptin Receptor Deficiency

Palatin’s Oral MC4R Agonist PL7737 Receives FDA Orphan ...

Mar 26, 2025 0

CRANBURY, N.J., March 25, 2025 /PRNewswire/ — Palatin Technologies, Inc. (NYSE A...

1
2
3

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.